These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 32961480)
1. Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors. Chen Z; Chen H; Zhang Z; Ding P; Yan X; Li Y; Zhang S; Gu Q; Zhou H; Xu J Eur J Med Chem; 2020 Nov; 206():112793. PubMed ID: 32961480 [TBL] [Abstract][Full Text] [Related]
2. Discovery of tissue selective liver X receptor agonists for the treatment of atherosclerosis without causing hepatic lipogenesis. Li C; Chen H; Chen X; Li Y; Hua P; Wei J; Song C; Gu Q; Zhou H; Zhang J; Xu J Eur J Med Chem; 2019 Nov; 182():111647. PubMed ID: 31499362 [TBL] [Abstract][Full Text] [Related]
3. Discovery of new LXRβ agonists as glioblastoma inhibitors. Chen H; Chen Z; Zhang Z; Li Y; Zhang S; Jiang F; Wei J; Ding P; Zhou H; Gu Q; Xu J Eur J Med Chem; 2020 May; 194():112240. PubMed ID: 32248003 [TBL] [Abstract][Full Text] [Related]
4. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists. Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261 [TBL] [Abstract][Full Text] [Related]
5. Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity. Karaboga H; Huang W; Srivastava S; Widmann S; Addanki S; Gamage KT; Mazhar Z; Ebalunode JO; Briggs JM; Gustafsson JÅ; Filgueira CS; Gilbertson SR; Lin CY ACS Chem Biol; 2020 Nov; 15(11):2916-2928. PubMed ID: 33074669 [TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. Li N; Wang X; Xu Y; Lin Y; Zhu N; Liu P; Lu D; Si S Mol Pharmacol; 2017 Apr; 91(4):264-276. PubMed ID: 28087808 [TBL] [Abstract][Full Text] [Related]
7. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist? Wu G; Wang Q; Xu Y; Li J; Zhang H; Qi G; Xia Q Cell Death Dis; 2019 May; 10(6):416. PubMed ID: 31138790 [TBL] [Abstract][Full Text] [Related]
8. Cholestenoic acid analogues as inverse agonists of the liver X receptors. Alvarez LD; Dansey MV; Ogara MF; Peña CI; Houtman R; Veleiro AS; Pecci A; Burton G J Steroid Biochem Mol Biol; 2020 May; 199():105585. PubMed ID: 31931135 [TBL] [Abstract][Full Text] [Related]
9. Development of new LXR modulators that regulate LXR target genes and reduce lipogenesis in human cell models. Høgmoen Åstrand OA; Gikling I; Sylte I; Rustan AC; Thoresen GH; Rongved P; Kase ET Eur J Med Chem; 2014 Mar; 74():258-63. PubMed ID: 24480357 [TBL] [Abstract][Full Text] [Related]
10. Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold. Goher SS; Griffett K; Hegazy L; Elagawany M; Arief MMH; Avdagic A; Banerjee S; Burris TP; Elgendy B Bioorg Med Chem Lett; 2019 Feb; 29(3):449-453. PubMed ID: 30587446 [TBL] [Abstract][Full Text] [Related]
11. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Na TY; Shin YK; Roh KJ; Kang SA; Hong I; Oh SJ; Seong JK; Park CK; Choi YL; Lee MO Hepatology; 2009 Apr; 49(4):1122-31. PubMed ID: 19105208 [TBL] [Abstract][Full Text] [Related]
12. Hypolipogenic Effect of Shikimic Acid Via Inhibition of MID1IP1 and Phosphorylation of AMPK/ACC. Kim MJ; Sim DY; Lee HM; Lee HJ; Kim SH Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30700011 [TBL] [Abstract][Full Text] [Related]
13. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor. Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875 [TBL] [Abstract][Full Text] [Related]